Department of Psychiatry, University of Cambridge, Cambridge, UK.
Child Adolesc Psychiatry Ment Health. 2008 Jan 29;2(1):3. doi: 10.1186/1753-2000-2-3.
A mood-related ruminative response style increases the risk of onset and persistence of depression. This preliminary study investigated whether, in depressed adolescents, cognitive-behaviour therapy reduces mood-related ruminative response style. Whether specific factors within the rumination scale were differentially affected by CBT is also reported.
26 depressed adolescents were randomised to receiving serotonin-specific reuptake inhibitor antidepressants (SSRI) plus psychosocial treatment as usual or SSRI and psychosocial treatment as usual plus CBT. Ruminative response style and depressive symptoms were measured at baseline and after 30 weeks of treatment, with the Responses to Depression Questionnaire and Mood and Feelings Questionnaire.
There were significantly greater reductions in ruminations in the CBT group compared to the non-CBT group (p = .002). There was no significant difference in the reduction in self-reported depressive symptoms between the groups. Rumination was reduced to levels of never-depressed controls in adolescents who had recovered from depression and received CBT. There were greater falls in the CBT group in the more pathological 'brooding' factor of rumination.
These findings suggest that adding CBT to SSRI medication in the presence of active clinical care causes a greater reduction in mood-related ruminative response style in depressed adolescents. This may reduce the risk of future relapse.
Current Controlled Trials ISRCNT83809224.
与情绪相关的反刍反应风格会增加抑郁发作和持续的风险。本初步研究调查了认知行为疗法是否会降低抑郁青少年的与情绪相关的反刍反应风格。报告了反刍量表内的特定因素是否会被 CBT 以不同的方式影响。
26 名抑郁青少年被随机分配接受选择性 5-羟色胺再摄取抑制剂(SSRI)抗抑郁药加常规心理社会治疗或 SSRI 和常规心理社会治疗加 CBT。在基线和 30 周治疗后,使用反应性抑郁问卷和心境和情感问卷测量反刍反应风格和抑郁症状。
CBT 组的反刍显著减少,与非 CBT 组相比(p =.002)。两组的自我报告抑郁症状减少没有显著差异。接受 CBT 的抑郁青少年恢复后,反刍减少到从未抑郁过的对照组的水平。在 CBT 组中,反刍的“沉思”这一更具病理性的因素下降幅度更大。
这些发现表明,在有积极临床护理的情况下,将 CBT 添加到 SSRI 药物治疗中,会导致抑郁青少年与情绪相关的反刍反应风格有更大的减少。这可能会降低未来复发的风险。
当前对照试验 ISRCTN83809224。